| Oct 1 |
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
|
| Sep 28 |
Aytu BioPharma Full Year 2024 Earnings: EPS Misses Expectations
|
| Sep 27 |
Q4 2024 Aytu Biopharma Inc Earnings Call
|
| Sep 26 |
Aytu BioPharma, Inc. (AYTU) Q4 2024 Earnings Call Transcript
|
| Sep 26 |
Aytu BioPharma files mixed offering
|
| Sep 26 |
Aytu BioPharma FY GAAP EPS of -$2.86 misses by $0.37, revenue of $81M misses by $0.33M
|
| Sep 26 |
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
|
| Sep 25 |
Aytu BioScience Q4 Earnings Preview
|
| Sep 19 |
Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024
|
| Sep 8 |
Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long
|
